Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparative effects of Quercetin and SRT1720 against D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: biochemical and molecular biological investigations

MK. Kemelo, A. Horinek, NK. Canová, H. Farghali,

. 2016 ; 20 (2) : 363-71.

Language English Country Italy

Document type Journal Article, Research Support, Non-U.S. Gov't

OBJECTIVE: Quercetin, a plant flavonoid with potent antioxidant action, has been shown to be ameliorative against different types of liver insults, including D-Galactosamine/Lipopolysaccharide (D-GalN/LPS). The notion that its cytoprotective effects are SIRT1 mediated is still controversial. In this work, we examined whether the synthetic allosteric SIRT1 activator, SRT1720, may similarly attenuate D-GalN/LPS-induced hepatotoxicity. MATERIALS AND METHODS: Male Wistar rats were randomly assigned into 6 groups: (1) Control, (2) Quercetin, (3) SRT1720, (4) D-GalN/LPS, (5) Quercetin + D-GalN/LPS and (6) SRT1720 + D-GalN/LPS. After twenty-four hours, the effects of these treatments were evaluated by biochemical studies, real-time PCR and Western blot. RESULTS: D-GalN/LPS treatment downregulated SIRT1 expression and markedly increased the aminotransferase, bilirubin and conjugated diene levels. Conversely, quercetin and SRT1720 pretreatments upregulated SIRT1 expression and decreased the levels of the aforementioned markers. Quercetin had more profound effect on SIRT1 expression than SRT1720. Moreover, quercetin was more efficacious than SRT1720 in combatting the cytotoxic effects of D-GalN/LPS, as evidenced by lower markers of liver injury. CONCLUSIONS: These results strongly suggest the involvement of SIRT1 in the cytoprotective effects of quercetin and SRT1720 against D-GalN/LPS-induced hepatotoxicity.

000      
00000naa a2200000 a 4500
001      
bmc16027668
003      
CZ-PrNML
005      
20161118104814.0
007      
ta
008      
161005s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)26875909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Kemelo, M K $u Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic. mighty.kemelo@lf1.cuni.cz.
245    10
$a Comparative effects of Quercetin and SRT1720 against D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: biochemical and molecular biological investigations / $c MK. Kemelo, A. Horinek, NK. Canová, H. Farghali,
520    9_
$a OBJECTIVE: Quercetin, a plant flavonoid with potent antioxidant action, has been shown to be ameliorative against different types of liver insults, including D-Galactosamine/Lipopolysaccharide (D-GalN/LPS). The notion that its cytoprotective effects are SIRT1 mediated is still controversial. In this work, we examined whether the synthetic allosteric SIRT1 activator, SRT1720, may similarly attenuate D-GalN/LPS-induced hepatotoxicity. MATERIALS AND METHODS: Male Wistar rats were randomly assigned into 6 groups: (1) Control, (2) Quercetin, (3) SRT1720, (4) D-GalN/LPS, (5) Quercetin + D-GalN/LPS and (6) SRT1720 + D-GalN/LPS. After twenty-four hours, the effects of these treatments were evaluated by biochemical studies, real-time PCR and Western blot. RESULTS: D-GalN/LPS treatment downregulated SIRT1 expression and markedly increased the aminotransferase, bilirubin and conjugated diene levels. Conversely, quercetin and SRT1720 pretreatments upregulated SIRT1 expression and decreased the levels of the aforementioned markers. Quercetin had more profound effect on SIRT1 expression than SRT1720. Moreover, quercetin was more efficacious than SRT1720 in combatting the cytotoxic effects of D-GalN/LPS, as evidenced by lower markers of liver injury. CONCLUSIONS: These results strongly suggest the involvement of SIRT1 in the cytoprotective effects of quercetin and SRT1720 against D-GalN/LPS-induced hepatotoxicity.
650    _2
$a alanintransaminasa $x metabolismus $7 D000410
650    _2
$a zvířata $7 D000818
650    _2
$a antioxidancia $x farmakologie $7 D000975
650    _2
$a bilirubin $x metabolismus $7 D001663
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a lékové postižení jater $x farmakoterapie $7 D056486
650    _2
$a galaktosamin $x škodlivé účinky $7 D005688
650    _2
$a heterocyklické sloučeniny tetra- a více cyklické $x farmakologie $7 D006576
650    _2
$a lipopolysacharidy $x škodlivé účinky $7 D008070
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a quercetin $x farmakologie $7 D011794
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a sirtuin 1 $x metabolismus $7 D056564
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horinek, A
700    1_
$a Canová, N K
700    1_
$a Farghali, H
773    0_
$w MED00190062 $t European review for medical and pharmacological sciences $x 2284-0729 $g Roč. 20, č. 2 (2016), s. 363-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26875909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161118104801 $b ABA008
999    __
$a ok $b bmc $g 1165982 $s 952298
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 20 $c 2 $d 363-71 $i 2284-0729 $m European review for medical and pharmacological sciences $n Eur Rev Med Pharmacol Sci $x MED00190062
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...